peptidylprolyl isomerase A pseudogene 49Genealiases: []
Q-omics provides the consensus-scored PPIAP49 profile across patient tissues and cancer cell-line models. PPIAP49 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, PPIAP49 is differentially expressed in 5, with the highest sampling consensus in LUAD. Additionally, PPIAP49 RNA expression shows 5,476 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight STAD, and LUAD as cancer lineages where PPIAP49 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPIAP49 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPIAP49 survival associations across molecular data types. PPIAP49 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPIAP49 RNA expression–survival associations across cancer types. High PPIAP49 expression shows unfavorable associations in STAD, UCEC, LUAD and MESO, but favorable associations in LUSC and ACC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for PPIAP49 RNA expression.
This table summarizes PPIAP49 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for PPIAP49. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPIAP49 shows lower tumor expression in PAAD and higher tumor expression in LUAD, HNSC, LIHC and KICH. The LUAD box plot shows higher PPIAP49 RNA expression in tumor versus normal tissue (log2 FC = +0.100, t-test p = .006).
This table shows molecular features associated with PPIAP49 in patient tissues and cancer cell lines. In patient samples, PPIAP49 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
